Clinical trials: Eye
Retinal Degenerations
Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
A small percentage of patients with retinal degeneration accumulate fluid in the center of their retina. Previous studies using an oral form of treatment has been successful in decreasing this fluid which improves vision.
- Trial name
- NCT00716586
- Testing
- 2% dorzolamide
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Illinois Chicago
Non-24-Hour Sleep-Wake Disorder
Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder
The purpose of this study is to evaluate the maintenance effect and safety of 20 mg tasimelteon versus placebo in subjects suffering from Non-24-Hour Sleep-Wake Disorder.
- Trial name
- NCT01430754
- Testing
- tasimelteon
- Where
- 22 sites in United States
- Volunteers
- 20 people
- Sponsor
- Vanda Pharmaceuticals
Glaucoma
Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)
A retrospective, non-interventional, observational, multi-center, chart review study to be conducted in participants who underwent placement of the XEN 45 Gel Stent as a standalone procedure or in combination with…
- Trial name
- NCT03868254
- Testing
- XEN Group, Phacoemulsification
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Allergan
Geographic Atrophy
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
- Trial name
- NCT03525613
- Testing
- APL-2
- Where
- 112 sites in United States, Australia and 12 more
- Volunteers
- 637 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Glaucoma
SDOCT-GMPE Software
The investigators prospectively evaluate the new glaucoma premium edition (GMPE) software for spectral domain optical coherence tomography (SDOCT) and if this software is superior to the conventional one that is currently used…
- Trial name
- NCT02235454
- Testing
- SDOCT-GMPE software
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Duke University
Ocular Hypertension
Effect of Alternate Therapies on Intraocular Pressure in Ocular Hypertension
The purpose of this study is to evaluate the effect of complementary and alternative therapies, specifically alternate nostril breathing and foot reflexology, on intraocular pressure in patients with ocular hypertension.
- Trial name
- NCT02993445
- Testing
- Alternate Nostril Breathing, Foot Reflexology
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Temple University
Cataract
Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)
The purpose of this study is to determine whether the use of OMS302 (the study drug) in individuals undergoing Cataract Extraction with Lens Replacement (CELR) surgery is safe and effective at maintaining an adequately dilated…
- Trial name
- NCT01193127
- Testing
- OMS302 Solution, OMS302 Mydriatic Solution, OMS302 Anti-inflammatory Solution
- Where
- 24 sites in United States
- Volunteers
- 223 people
- Sponsor
- Omeros Corporation
Retinal Dystrophies, Healthy
Optical Head-Mounted Display Technology for Low Vision Rehabilitation
The goal of this study is to examine the ability of optical head-mounted display technology to enlarge the visual field of patients with severe visual field loss due to retinal dystrophy and to improve mobility and…
- Trial name
- NCT02983305
- Testing
- Head-Mounted Display
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Intraocular Pressure, Glaucoma
24-hour IOP-lowering Effect of 0.01% Bimatoprost
This study will evaluate the 24-hour IOP-lowering efficacy of 0.01% bimatoprost once daily in patients with glaucoma or ocular hypertension
- Conditions
- Intraocular Pressure, Glaucoma, Ocular Hypertension
- Trial name
- NCT01271686
- Testing
- 0.01% bimatoprost
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Diego
Myopia
Overall Performance of a 1-day Silicone Hydrogel Lens When Habitual Soft Lens Wearers Are Refit
The objective of the study is to compare the overall subjective comfort profile over 8 hours of lens wear in two groups of habitual soft contact lens wearers (daily disposable hydrogel lenses and frequent replacement lenses) when…
- Trial name
- NCT02588573
- Testing
- etafilcon A (control), somofilcon A (test)
- Where
- 2 sites in Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- CooperVision, Inc.
Cataract
Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension
A randomized, multicenter, double masked, placebo controlled, parallel group, bioequivalence study to evaluate the clinical equivalence and safety of Nepafenac 0.3% ophthalmic suspension (manufactured by Indoco remedies Ltd.
- Trial name
- NCT03499873
- Testing
- Nepafenac 0.3% Oph Susp, Nepafenac 0.3% Oph Susp (reference)
- Where
- United States
- Volunteers
- 448 people
- Sponsor
- Actavis Inc.
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT01805037
- Testing
- brentuximab vedotin, rituximab, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
The goal of this clinical research study is to learn if the combination of oblimersen sodium and rituximab can help to shrink or slow the growth of the tumor in patients with B-cell non-Hodgkin's lymphoma who have not responded…
- Conditions
- Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT00054639
- Testing
- oblimersen sodium, rituximab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Glaucoma
Improve Glaucoma Medication Adherence
The proposed study is a randomized controlled trial enrolling Veterans with medically treated glaucoma who report less than 100% adherence to the prescribed glaucoma therapy.
- Trial name
- MAGIC (NCT03052257)
- Testing
- Educational - glaucoma, Dose monitoring and reminder, Educational - general
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- VA Office of Research and Development
Primary Open-Angle Glaucoma, Ocular Hypertension
Dose-Ranging Study of the Bimatoprost Ocular Insert
The Bimatoprost Ocular Insert is intended to provide sustained delivery of bimatoprost to the ocular surface to lower the intraocular pressure (IOP) in patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT02358369
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 156 people
- Sponsor
- ForSight Vision5, Inc.
Myopic Astigmatism
STAAR Visian Toric ICL Post-Approval Study
The objective of this study is to evaluate the long term (i.e. 24 months) clinical performance of the Visian® Toric Implantable Collamer® Lens (ICL).
- Trial name
- TICL-PAS (NCT04516772)
- Testing
- Visian TICL
- Where
- 8 sites in United States
- Volunteers
- 125 people
- Sponsor
- Staar Surgical Company
Diabetic Retinopathy, Diabetic Macular Edema
Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema
The purpose of the study is to find out which is a better treatment for diabetic macular edema (DME): laser alone, laser combined with an intravitreal injection of triamcinolone, laser combined with an intravitreal injection of…
- Trial name
- LRT for DME (NCT00444600)
- Testing
- Triamcinolone Acetonide + laser, Ranibizumab + laser, Ranibizumab + deferred laser
- Where
- 50 sites in United States
- Volunteers
- 691 people
- Sponsor
- Jaeb Center for Health Research
Presbyopia
1-Week Dispensing Evaluation of Kalifilcon A Daily Disposable Multifocal Compared to Ultra for Presbyopia
Experienced soft contact lens wearing subjects will be enrolled in this 1-week, confirmatory, randomized, bilateral, 2-way crossover, double masked (subject and investigator), repeated measures, dispensing study.
- Trial name
- NCT05325931
- Testing
- kalifilcon A Daily Disposable Multifocal, samfilcon A for Presbyopia
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Age-Related Macular Degeneration, Retinal Vein Occlusion
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
This study was conducted because the FDA requested clinical information on potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium from a 1-year (minimum) post-approval…
- Conditions
- Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT01573572
- Testing
- pegaptanib sodium injection
- Where
- 4 sites in United States
- Volunteers
- 131 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Syndromes
Pilot Study of TearCare System - Long-Term Extension
The objective of the study is to evaluate the long-term clinical utility, safety, and effectiveness of re-treatment with the TearCare™ System in adult patients with dry eye syndrome who had previously been treated with the…
- Trial name
- NCT03804502
- Testing
- TearCare
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sight Sciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.